Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + surufatinib in second-line extensive-stage small cell lung cancer
ChiCTR2500101507Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and surufatinib in small cell lung cancer (SCLC), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective response rate. Started Apr 2025; status: recruiting.
02
Drugs
cadonilimabsurufatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500101507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101507.